business

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

Yahoo Finance · Jun 30, 2026, 1:06 PM · Also reported by 2 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

CNBC French biotech stock soars 31% after new data on experimental medicine Investing.com Citizens initiates Klarna stock coverage at Market Perform

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

Also covered by

More in business